title: Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To investigate whether there is an association of the LOC387715 A69S genotype with visual prognosis after photodynamic therapy in eyes with polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Photodynamic therapy was repeated every 3 months until the disappearance of angiographic signs of active lesions in 71 eyes of 71 patients with PCV who were followed-up for at least 12 months. All patients were genotyped for LOC387715 A69S polymorphism (rs10490924, risk-allele T).
  
  
  RESULTS
  Although there was no statistically significant difference in the mean baseline visual acuity (P = 0.53) among the 3 genotypes, there was a statistically significant difference in the visual acuity both at the 12-month and final visits (P = 0.002 and P < 0.001, respectively) with the poorer acuity in patients with the higher "T-"allele frequency. "T" allele was more frequently observed in those with the recurred PCV lesions (odds ratio: 5.8, 95% confidential interval: 2.3-15.1, T vs. G).
  
  
  CONCLUSIONS
  There is a pharmacogenetic association between the LOC387715 A69S variant and the long-term results after photodynamic therapy in eyes with PCV. The LOC387715 A69S genotype is of clinical importance to predict the visual prognosis after photodynamic therapy in eyes with PCV. These results should be confirmed or refuted by replication studies.
authors.affiliation: Department of Opthalmology, Faculty of Medicine, University of Yamanashi, Shimokato, Yamanashi, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Sakurada
authors.forename: Takeo
authors.initials: T
authors.lastname: Kubota
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Imasawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Mabuchi
authors.forename: Naohiko
authors.initials: N
authors.lastname: Tanabe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Iijima
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002829:Choroid / Q000098:blood supply; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D007208:Indocyanine Green; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011379:Prognosis; D011506:Proteins / Q000235:genetics*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology*
chemical_list: C514392:ARMS2 protein, human; D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D011506:Proteins; D000077362:Verteporfin; D007208:Indocyanine Green